Perspectives in Liver Transplantation

You have full text access to this OnlineOpen article

Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: A case report

  1. Gaël Piton1,5,
  2. Fabrice Larosa2,5,
  3. Anne Minello6,
  4. Marie-Claude Becker1,5,
  5. Georges Mantion3,5,
  6. François Aubin4,5,
  7. Eric Deconinck2,5,
  8. Patrick Hillon6,
  9. Vincent Di Martino1,5,†,*

Article first published online: 26 JUN 2009

DOI: 10.1002/lt.21793

Issue

Liver Transplantation

Liver Transplantation

Volume 15, Issue 7, pages 682–685, July 2009

Additional Information

How to Cite

Piton, G., Larosa, F., Minello, A., Becker, M.-C., Mantion, G., Aubin, F., Deconinck, E., Hillon, P. and Di Martino, V. (2009), Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: A case report. Liver Transpl, 15: 682–685. doi: 10.1002/lt.21793

Author Information

  1. 1

    Service d'Hépatologie, Université de Franche Comté et Centre Hospitalier Universitaire de Besançon, Besançon, France

  2. 2

    Service d'Hématologie, Université de Franche Comté et Centre Hospitalier Universitaire de Besançon, Besançon, France

  3. 3

    Service de Chirurgie Digestive et Transplantation, Université de Franche Comté et Centre Hospitalier Universitaire de Besançon, Besançon, France

  4. 4

    Service de Dermatologie, Université de Franche Comté et Centre Hospitalier Universitaire de Besançon, Besançon, France

  5. 5

    Centre d'Investigation Clinique, Centre Hospitalier Universitaire Jean Minjoz, Besançon, France

  6. 6

    Service d'Hépatogastroenterologie, Centre Hospitalier Universitaire du Bocage, Dijon, France

  1. †

    Telephone: 33 381668421; FAX: 33 381668417

*Service d'Hépatologie, Centre Hospitalier Universitaire Jean Minjoz, 25000 Besançon, France

Publication History

  1. Issue published online: 26 JUN 2009
  2. Article first published online: 26 JUN 2009
  3. Manuscript Accepted: 11 MAR 2009
  4. Manuscript Received: 11 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (80K)

REFERENCES

  • 1
    Burdick JF, Vogelsang GB, Smith WJ, Farmer ER, Bias WB, Kaufmann SH, et al. Severe graft-versus-host disease in a liver-transplant recipient. N Engl J Med 1988; 318: 689–691.
  • 2
    Perri R, Assi M, Talwalkar J, Heimbach J, Hogan W, Moore SB, et al. Graft vs. host disease after liver transplantation: a new approach is needed. Liver Transpl 2007; 13: 1092–1099.
    Direct Link:
  • 3
    Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004; 89: 1352–1359.
  • 4
    Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–1847.
  • 5
    Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C, et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055–1060.
  • 6
    Chan EY, Larson AM, Gernsheimer TB, Kowdley KV, Carithers RL Jr, Reyes JD, et al. Recipient and donor factors influence the incidence of graft-vs.-host disease in liver transplant patients. Liver Transpl 2007; 13: 516–522.
    Direct Link:
  • 7
    Smith DM, Agura E, Netto G, Collins R, Levy M, Goldstein R, et al. Liver transplant-associated graft-versus-host disease. Transplantation 2003; 75: 118–126.
  • 8
    Taylor AL, Gibbs P, Sudhindran S, Key T, Goodman RS, Morgan CH, et al. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation. Transplantation 2004; 77: 441–446.
  • 9
    Taylor AL, Gibbs P, Bradley JA. Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant 2004; 4: 466–474.
    Direct Link:
  • 10
    Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992; 101: 1481–1483.
  • 11
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932–1939.
  • 12
    Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.
  • 13
    Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–2476.
  • 14
    Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357: 1842–1847.
  • 15
    Herve P, Flesch M, Tiberghien P, Wijdenes J, Racadot E, Bordigoni P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362–3368.
  • 16
    Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004; 104: 649–654.
  • 17
    Jacobsohn DA, Hallick J, Anders V, McMillan S, Morris L, Vogelsang GB. Infliximab for steroid-refractory acute GVHD: a case series. Am J Hematol 2003; 74: 119–124.
    Direct Link:
  • 18
    Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001; 28: 47–49.
  • 19
    Nogueira MC, Azevedo AM, Pereira SC, Ferreira JL, Lerner D, Lobo AM, et al. Anti-tumor necrosis factor-a for the treatment of steroid-refractory acute graft-versus-host disease. Braz J Med Biol Res 2007; 40: 1623–1629.
  • 20
    Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999; 5: 347–356.
  • 21
    Holler E, Kolb HJ, Moller A, Kempeni J, Liesenfeld S, Pechumer H, et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011–1016.
  • 22
    Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76: 1742–1749.
  • 23
    Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000; 95: 2754–2759.
  • 24
    Duvoux C, Pageaux GP, Vanlemmens C, Roudot-Thoraval F, Vincens-Rolland AL, Hezode C, et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: an analysis of 480 patients. Transplantation 2002; 74: 1103–1109.
  • 25
    Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275–2285.
  • 26
    Domiati-Saad R, Klintmalm GB, Netto G, Agura ED, Chinnakotla S, Smith DM. Acute graft versus host disease after liver transplantation: patterns of lymphocyte chimerism. Am J Transplant 2005; 5: 2968–2973.
    Direct Link:
View Full Article (HTML) Get PDF (80K)